Access cutting-edge severe alopecia areata treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Indianapolis location
Preparing your pre-screening questions…
Access severe alopecia areata specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related severe alopecia areata treatment provided free
Check if you qualify for this severe alopecia areata clinical trial in Indianapolis, IN
No-Cost Study Care
Local to Indianapolis
Convenient for IN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss. This study is seeking participants who have: * previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031). * at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031). * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports. All participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial. Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial. The study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home. The study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.
Sponsor: Pfizer
Yes, this clinical trial (NCT07029828) has an active research site in Indianapolis, IN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for severe alopecia areata treatment options in Indianapolis, IN, this clinical trial (NCT07029828) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced severe alopecia areata specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all severe alopecia areata clinical trials near you to find additional studies recruiting in your area.
See all pulmonary embolism clinical trials recruiting in Indianapolis — not just this study.
Browse Pulmonary Embolism Trials in Indianapolis →